Premium
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Author(s) -
Gonzalez de Castro D,
Clarke P A,
AlLazikani B,
Workman P
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.237
Subject(s) - personalized medicine , epidermal growth factor receptor , precision medicine , cancer , drug resistance , computational biology , lung cancer , molecular diagnostics , bioinformatics , medicine , molecular biomarkers , drug discovery , drug , biology , pharmacology , oncology , genetics , pathology
The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution. Clinical Pharmacology & Therapeutics (2013); 93 3, 252–259. doi: 10.1038/clpt.2012.237